TORONTO – A total of $1.4 million in capital funding from 12 U.S., Canadian and European angel investors will help Toronto-based Cohesys Inc. complete preclinical animal studies, with an eye toward gaining approval for its nontoxic, adhesive tape for rebuilding facial bones.
The U.S. Department of Justice (DoJ) has taken action to tamp down on False Claims Act (FCA) lawsuits. However, according to attorneys with the law firm of Gibson, Dunn & Crutcher LLP, the courts have come to different conclusions as to whether federal attorneys have appropriately dismissed FCA cases, a development that opens a new area of concern for drug and device makers.
Medtronic plc, of Dublin, has had a busy week. On Tuesday, it reported that it had received breakthrough device designation from the U.S. FDA for its Valiant TAAA stent graft system for the minimally invasive repair of thoracoabdominal aortic aneurysm (TAAA).